subscribeSubscribe
price-trendAsk Us
Ovid pens deal to offload twice-failed former lead program

Ovid pens deal to offload twice-failed former lead program
H. Shasteen BIOSPACE
09 Feb 2022
Share Share
Ovid`s Angelman syndrome therapy falls short at Phase 3

Ovid`s Angelman syndrome therapy falls short at Phase 3
PHARMAFILE
02 Dec 2020
Share Share
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020

Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020
PRESSRELEASE
23 Nov 2020
Share Share
Angelini lands EU rights to Ovid`s phase 3 rare disease drug

Angelini lands EU rights to Ovid`s phase 3 rare disease drug
Nick P Taylor FIERCE BIOTECH
14 Jul 2020
Share Share
Ovid Therapeutics Announces +ve Topline Results from Ph2 ROCKET Trial of OV101

Ovid Therapeutics Announces +ve Topline Results from Ph2 ROCKET Trial of OV101
PRESS RELEASE
08 May 2020
Share Share